Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

NEULAND LABORATORIES LTD.

NSE : NEULANDLABBSE : 524558ISIN CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse : Private

BSE14547.75-751.15 (-4.91 %)

PREV CLOSE ( ) 15298.90

OPEN PRICE ( ) 15001.00

BID PRICE (QTY) 14529.25 (5)

OFFER PRICE (QTY) 14549.95 (4)

VOLUME 11696

TODAY'S LOW / HIGH ( )14437.00 15001.00

52 WK LOW / HIGH ( )7900 18089.55

NSE14464.00-809 (-5.3 %)

PREV CLOSE( ) 15273.00

OPEN PRICE ( ) 15010.00

BID PRICE (QTY) 14464.00 (84)

OFFER PRICE (QTY) 14465.00 (108)

VOLUME 102398

TODAY'S LOW / HIGH( ) 14451.00 15010.00

52 WK LOW / HIGH ( )7920.1 18100

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 07-01 1984

Management Info

Davuluri Rama Mohan Rao - Chairman Davuluri Saharsh Rao - Managing Director

Registered Office

Address 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee Hills,
Hyderabad,
Telangana-500033

Phone 040-67611600 / 67611700

Email neuland@neulandlabs.com

Website www.neulandlabs.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

05Jul Neuland Laboratories informs about new
Pursuant to Regulation 47 of the Securities and Exchange Board of India..

21Jun Neuland Laboratories informs about cre
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..

17Jun Neuland Laboratories informs about iss
Pursuant to the Regulation 39(3) of the SEBI (Listing Obligations and Di..

17Jun Neuland Laboratories informs about new
Pursuant to Regulation 47 of the Securities and Exchange Board of India..

17Jun Neuland Laboratories informs about ne
Pursuant to Regulation 47 of the Securities and Exchange Board of India..

Financials

Rs. in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	277.34	2594.26
Gross Profit	389.82	3453.74
Operating Profit	582.18	3428.08
Net Sales	3283.6	14768.37

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

SMS Lifesciences (BSE) 1343.30 (17.44%)	M.Cap ( in Cr)397.99
RPG Life Sciences (BSE) 2640.00 (3.25%)	M.Cap ( in Cr)4325.12
Sanofi Cons. Health (BSE) 5207.05 (1.59%)	M.Cap ( in Cr)12031.08
Procter&Gamble Healt (BSE) 5931.80 (1.15%)	M.Cap ( in Cr)9883.69
Gland Pharma (BSE) 1960.85 (3.41%)	M.Cap ( in Cr)32300.50

Shareholding Pattern

	NON-INSTITUTION	33.84%
	PROMOTERS	32.68%
	MUTUAL FUNDS/UTI	7.43%
	FI/BANKS/INSURANCE	0.96%
	GOVERNMENT	0.4%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
LIC MF Healthcare F...	4.12
Bajaj Finserv Healt...	2.78
ITI Pharma & Health...	2.08
PGIM India Healthca...	1.82
HSBC Focused Fund-Reg(G)	1.74
Tata Nifty MidSmall...	1.74
Motilal Oswal Nifty...	1.73

Risk Disclosures on Derivatives

Smart Quotes

NEULAND LABORATORIES LTD.